Differentiating SIADH from Cerebral/Renal Salt Wasting: Failure of the Volume Approach and Need for a New Approach to Hyponatremia by Maesaka, John K. et al.







Differentiating SIADH from Cerebral/Renal Salt Wasting: 
Failure of the Volume Approach and Need for a New Approach 
to Hyponatremia 
John K. Maesaka 1,*, Louis Imbriano 1,†, Joseph Mattana 1,†, Dympna Gallagher 2,†,  
Naveen Bade 1,† and Sairah Sharif 1,† 
1 Department of Medicine, Winthrop-University Hospital, Mineola, NY 11501, USA;  
E-Mails: limbriano@winthrop.org (L.I.); jmattana@winthrop.org (J.M.);  
nbade@winthrop.org (N.B.); ssharif@winthrop.org (S.S.) 
2 Department of Medicine, Columbia University, New York, NY 10027, USA;  
E-Mail: dg108@columbia.edu 
† These authors contributed equally to this work. 
* Author to whom correspondence should be addressed; E-Mail: jmaesaka@winthrop.org;  
Tel.: +1-516-663-2169; Fax: +1-516-663-2179. 
Received: 7 July 2014; in revised form: 26 August 2014 / Accepted: 9 September 2014 /  
Published: 8 December 2014 
 
Abstract: Hyponatremia is the most common electrolyte abnormality. Its diagnostic and 
therapeutic approaches are in a state of flux. It is evident that hyponatremic patients are 
symptomatic with a potential for serious consequences at sodium levels that were once 
considered trivial. The recommendation to treat virtually all hyponatremics exposes the need 
to resolve the diagnostic and therapeutic dilemma of deciding whether to water restrict  
a patient with the syndrome of inappropriate antidiuretic hormone secretion (SIADH) or 
administer salt and water to a renal salt waster. In this review, we briefly discuss the 
pathophysiology of SIADH and renal salt wasting (RSW), and the difficulty in 
differentiating SIADH from RSW, and review the origin of the perceived rarity of RSW, as 
well as the value of determining fractional excretion of urate (FEurate) in differentiating both 
syndromes, the high prevalence of RSW which highlights the inadequacy of the volume 
approach to hyponatremia, the importance of changing cerebral salt wasting to RSW, and the 
proposal to eliminate reset osmostat as a subtype of SIADH, and finally propose a new 
algorithm to replace the outmoded volume approach by highlighting FEurate. This algorithm 
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eliminates the need to assess the volume status with less reliance on determining urine sodium 
concentration, plasma renin, aldosterone and atrial/brain natriuretic peptide or the BUN to 
creatinine ratio. 
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1. Introduction 
Hyponatremia, defined as serum sodium <135 mEq/L, is the most common electrolyte abnormality 
encountered worldwide and is an independent risk factor for higher morbidity and mortality rates [1,2]. 
Symptoms related to hyponatremia have been traditionally associated with severe hyponatremia and 
acute reductions in serum sodium, but there is a growing awareness that even mild hyponatremia is 
associated with mental dysfunction, unsteady gait, osteoporosis, increased falls and bone fractures [3–9]. 
Based on this awareness, there is an evolving tendency to treat every patient with hyponatremia. This 
recommendation creates an urgent need to assess with assurance the cause of the hyponatremia in  
a group of patients with diverse clinical associations and different therapeutic goals. Unfortunately,  
the present volume approach to hyponatremia, which has been in existence for decades, has been 
inadequate and misleading, in part because of misconceptions that are unsubstantiated by supportive 
data. Foremost among the misconceptions is the common but unproven perception that cerebral salt 
wasting (CSW) is a rare clinical entity. Clarification of cerebral, or the more appropriate term, renal 
salt wasting (RSW), vide infra, and its differentiation from SIADH becomes critical because of 
opposing therapeutic goals, which are to provide salt and water to a volume depleted patient with  
RSW and water restriction for a water-loaded patient with SIADH. We intend to briefly discuss the 
pathophysiology of RSW and SIADH, current methods of differentiating SIADH from RSW, the failure 
of the volume approach to address hyponatremia which has resulted in misconceptions and 
mismanagement of many hyponatremic patients, present data to support our proposal to change CSW 
to RSW, and removing reset osmostat (RO) as a subtype of SIADH, and present an algorithm which 
eliminates the need to assess volume, determine urine sodium concentration (UNa), plasma renin, 
aldosterone or atrial/brain natriuretic peptide (A/BNP). 
2. Pathophysiology of RSW and SIADH and Evolution of Controversy on Rarity of Cerebral  
Salt Wasting 
The initiation of RSW starts with the stimulation of a natriuretic factor that reduces sodium 
transport to induce RSW and extracellular volume (ECV) depletion, which in turn stimulates secretion 
of antidiuretic hormone (ADH), renin and aldosterone and decreases atrial/brain natriuretic peptide 
(A/BNP). The volume stimulus for ADH secretion is common to any state where there is ineffective 
circulatory volume be it heart failure or true volume depletion. The volume stimulus is more potent 
than the osmolar stimulus so a volume depleted patient continues to secrete ADH despite becoming 
progressively hyponatremic as long as the patient continues to take in free water [10]. Removal of the 
volume stimulus allows the coexistent hypo-osmolality to inhibit ADH secretion, remove water from 
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the body by excreting dilute urines and correcting the hyponatremia to illustrate appropriate ADH 
secretion in RSW [11,12]. As previously reviewed, the first descriptions of CSW failed to prove with 
certainty a salt wasting syndrome [13,14]. RSW was possible in one patient who was described as 
being dehydrated with a urine chloride of 61.6 mEq/L [13]. Previous studies have demonstrated that  
a sodium depleted patient will virtually eliminate sodium from urine until the sodium losses have been 
replaced [15–17]. The high urine chloride and presumably sodium concentration in urine would, thus, 
have been consistent with RSW and the term CSW was thus derived. 
SIADH evolved as a clinical entity by the demonstration of a clinical correlate to the seminal work by 
Leaf et al., who defined the consequences of administering vasopressin to normal human subjects [18]. 
The proposal of an inappropriate secretion of ADH in the absence of methods to determine plasma 
ADH levels epitomized the application of basic physiologic principles to the bedside [19]. This 
hypothesis was later proven by demonstrating inappropriately high ADH levels that did not respond to 
the usual volume and osmolar stimuli [19]. Moreover, ECV measured by the sulfate method in the first 
reported case of SIADH proved that it was possible for a euvolemic/hypervolemic patient to have 
hyponatremia with high UNa without implicating a renal salt wasting syndrome [19]. An increase in 
intravascular volume by the gold standard radioisotope dilution method has been demonstrated by 
others in SIADH [12,20,21]. It became evident that the original case of CSW in a “dehydrated” patient 
with high UNa could have had SIADH because of the general agreement that one cannot accurately 
assess volume status by usual clinical criteria. The existence of CSW, therefore, was seriously 
questioned to the point of being considered either nonexistent or certainly rare.  
3. Differentiating SIADH from RSW 
Differentiating SIADH from RSW has been extremely difficult to accomplish, in part because  
of significant overlapping clinical findings between both syndromes. As noted in Table 1, both 
syndromes are associated with intracranial diseases, have normal renal, thyroid and adrenal function, 
are hyponatremic and hypouricemic and have concentrated urines, high UNa over 40 mEq/L, and  
high fractional excretion (FE) of urate. The only clinical difference is the state of their ECV, being 
euvolemic or hypervolemic in SIADH and hypovolemic in RSW. The overlapping of major clinical 
characteristics between SIADH and RSW as noted in Table 1 and the perception that RSW is a rare 
clinical entity have virtually eliminated RSW from consideration at the bedside. This diagnostic 
dilemma needs to be urgently resolved because of the evolving awareness that even mildly 
hyponatremic patients are symptomatic and should therefore be treated [5,7]. These perceptions and 
recommendations are in large part influenced by reports of unsteady gait and a fourfold increase in fall 
rates which appears to be consistent from a serum sodium of 115–132 mEq/L. In addition, a fourfold 
increase in bone fractures in elderly hyponatremic patients and increased osteoporosis with chronic 
hyponatremia has been reported [5,7,22]. The urgency in resolving the diagnostic and therapeutic 
dilemma becomes most evident by the divergence in therapeutic goals of water restricting patients with 
SIADH and administering salt and water in RSW.  
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Table 1. List of features common to syndrome of inappropriate antidiuretic hormone 
secretion (SIADH) and renal salt wasting (RSW), except divergent volume status. 
Clinical Findings Common to both SIADH and RSW 
Association with intracranial disease 
Hyponatremia 
Concentrated urine 
Urine sodium [Na] usually >20 mEq/L 
Non-edematous 
Hypouricemia, with increased fractional excretion urate (FEurate) 
Only Difference between SIADH and RSW 
Volume state: normal/high in SIADH 
low in RSW 
There is universal agreement that we cannot assess ECV with any degree of accuracy by usual clinical 
criteria, yet the approach to hyponatremia starts with an assessment of volume. The ineffectiveness of 
this volume approach is becoming even more evident by an objective review of the literature and recent 
publications of RSW occurring in patients without clinical cerebral disease [11,12]. Since an assessment 
of volume is essential in differentiating SIADH from RSW, let us review studies that have determined 
volume by credible methods. As noted in Table 2, 83%–94% of hyponatremic patients with different 
forms of neurosurgical diseases were found to have hypovolemia with high UNa that met the criteria 
for RSW as compared to hypervolemic patients with SIADH. Blood volume was determined by gold 
standard radioisotope dilution methods, including 51 chromium labeled red cells and/or radio iodinated 
serum albumin (RISA) [20,21,23]. It is clear from these studies that RSW is much more common than 
SIADH, yet it is still perceived as a rare clinical entity, which has been propagated for many years 
without either negating these compelling studies nor by providing evidence to the contrary by suitable 
methods. Moreover, water restricting these patients for an erroneous diagnosis of SIADH when in fact 
they have RSW has been reported to increase morbidity and mortality rates in patients with subarachnoid 
hemorrhage [12,24,25]. These data emphasize the importance of differentiating SIADH from RSW in 
order to develop better targeted therapeutic strategies. 
Table 2. Summary of volume studies by gold standard radio-isotope dilution methods in 




Low Blood Volume 
RSW 
Increased Blood Volume 
SIADH 
Urine Na mEq/L
Nelson [20] 12 10 (83%) 2 41–203  
Wijdicks [21] 9 8 (89%) 1 --  
Sivakumar [23] 18 17 (94%)  43–210  
4. Value of Determining FEurate in Differentiating SIADH from RSW and Changing CSW  
to RSW 
Calculation of fractional excretion (FE) of urate determines the percent excretion of the filtered load 
of urate at the glomerulus. It determines the net transport of urate without distinguishing what is 
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secreted or reabsorbed and can be readily determined by collecting blood and spot urine at the same 
time. FEurate in percentage excretion of the filtered load of urate can be determined by dividing the 
ratio of urine to plasma urate by the ratio of urine to plasma creatinine and multiplying by 100. It can 
also be derived by dividing the product of UNa (×) serum urate by the product of serum sodium (×) 
urine creatinine and multiplying by 100. FEurate, normal 4%–11%, has been consistently increased to 
>11% in SIADH and RSW and has a unique relationship to serum sodium in SIADH and RSW. In 
SIADH, correction of hyponatremia will normalize FEurate to 4%–11% as compared to being 
persistently increased to >11% in RSW, Figure 1 [26–29]. The relationship between FEurate and 
serum sodium can now be utilized to differentiate SIADH from RSW by correcting the hyponatremia 
by any means, be it by water restriction or isotonic/hypertonic saline and observing whether FEurate 
normalizes to 4%–11% as in SIADH or remains increased above 11% in RSW, Figure 1 [11,12,30–33]. 
FEurate can exceed normal values in patients with reduced GFR, so the algorithm is valid in patients 
with serum creatinine less than 1.5 mg/dL. 
Figure 1. Changes in FEurate in SIADH and RSW after correction of hyponatremia. 
Shaded areas represent normal ranges. (Maesaka J. K., modified from [14]). 
 
Two unequivocal cases of RSW without clinical evidence of cerebral disease not only verified the 
persistent increase in FEurate with correction of hyponatremia, but served as the basis for us to make  
a clinically important proposal to change CSW to RSW [11,12,34]. One was a hyponatremic patient 
with a simple hip fracture with no clinical evidence of cerebral disease who exhibited all of the 
essential features of RSW. The hyponatremia was associated with a 7% reduction in blood volume as 
determined by the gold standard radioisotope dilution method, using 51 chromium labeled red blood 
cells and RISA, increased baseline plasma renin, aldosterone, and ADH and low normal atrial 
natriuretic peptide. She diluted her urine to 170 mOsm/kg 13 h after initiation of saline therapy when 
her plasma ADH level was not detectable. Her serum sodium increased to 138 mEq/L within 48 h 
(Figure 2), and the increased FEurate persisted with normalization of serum sodium (Figure 1) [12]. A 
similar case of RSW was a hyponatremic patient with a pneumonia without cerebral disease, who 
diluted his urine 20 h after initiating saline therapy [11]. As in the hip fracture patient, the increased 
FEurate persisted after volume repletion and correction of hyponatremia. A water loading test was 




Before                After                Before           After
Correction of Hyponatremia
J. Clin. Med. 2014, 3 1378 
 
 
a hip fracture, there was an appropriate hypovolemia-induced increase in ADH. Saline infusions 
eliminated the volume stimulus for ADH secretion to allow the coexistent plasma hypo-osmolality to 
inhibit ADH secretion, thereby excreting dilute urines and correcting the hyponatremia [11,12]. In two 
patients with SIADH and increased blood volumes, saline infusion failed to dilute their urine or correct 
their hyponatremia [11]. 
Figure 2. Correction of serum sodium and achievement of dilute urine after saline infusion 
(with permission, Kidney International, Maesaka J. K. [12]). 
 
The relationship between serum sodium and FEurate as noted in Figure 1 may be the best available 
method to differentiate SIADH from RSW. Correction of the hyponatremia can be accomplished by  
any method, including hypertonic saline, to differentiate SIADH from RSW. Many consider the 
administration of saline to be a detriment to the evaluation of the hyponatremic patient because of its 
effect on UNa and plasma renin, aldosterone and A/BNP. As extensively reviewed in our review of 
renal urate transport, we cite four papers that demonstrate the meager effect of saline infusions on 
FEurate, Table 3 [35–38]. The meager effect of saline on FEurate can be illustrated in a hyponatremic 
patient with high FEurate who posed a diagnostic dilemma of not being able to determine whether the 
patient had SIADH or RSW. The diagnosis of SIADH was made by increasing serum sodium to 138 
mEq/L by administering liberal amounts of isotonic and hypertonic saline and observing a marked 
decrease in FEurate from 26% to 8% [32]. The marked reduction in FEurate after the administration of 
isotonic and hypertonic saline is contradictory to the common belief that saline reduces the net 
transport of many solutes, including urate. The reduction in FEurate after correction of hyponatremia 
by isotonic and hypertonic saline raises an intriguing question as to why FEurate would normalize in 
SIADH and remain increased in RSW. As previously reviewed, the increase in FEurate cannot be 
explained by the V1 activity of ADH or chronic hyponatremia in SIADH but it is probable that the 
natriuretic factor demonstrated in RSW might reduce urate transport in the proximal tubule where 
urate is exclusively transported and is the major site of inhibiting sodium transport by the natriuretic 
factor [39–41]. 
J. Clin. Med. 2014, 3 1379 
 
 
Table 3. Summary of extracellular volume expansion with isotonic, hypotonic and 
hypertonic saline on fractional excretion of sodium [FEsodium] and urate [FEurate] at 
control and experimental (Exp.) periods after saline administration. 
 
FE Na (%) FE Urate (%) 
Reference 
Control Exp. Control Exp.  
Isotonic 1.04 4.43 7.98 9.76  [37] 
 1.6 8.2 5.0 5.8  [36] 
Hypertonic 2.9 18.6 5.4 12.1  [36] 
 1.4 14.5 12.5 18.7  [35] 
Hypotonic 1.1 6.1 4.0 7.3  [36] 
5. Normal FEurate Identifies Patients with Reset Osmostat 
The value of determining FEurate in hyponatremic conditions has been further amplified by a 
normal FEurate being observed in every hyponatremic patient with RO [42]. The normal FEurate seen 
in psychogenic polydipsia and possibly in beer potomania can be readily identified by the history of 
excess intake of water or beer, respectively [42,43]. Based on these data, we proposed eliminating RO 
as type C SIADH because of the normal FEurate, which is pathophysiologically different from the 
high FEurate seen in SIADH, and a predictable response to water-loading [42]. 
6. Proposal of New Algorithm 
Based on a large database, we would like to introduce a new, updated algorithm which centers on 
the determination of FEurate outlined in Figure 3. Each citation can be supported by credible data. 
This algorithm has been found to be superior to the traditional volume approach, which has been used 
for decades and is clearly inadequate. Once the patient has been identified to have hyponatremia, 
defined usually to be a serum sodium <135 mEq/L, we suggest determining FEurate by obtaining a 
spot blood and urine sample and utilizing the formula provided above. The administration of saline 
should not affect the FEurate to any significant degree (Table 3), and drugs such as atorvastatin and 
losartan which are known to increase urate excretion have not been shown to have a meaningful effect 
on the results [44,45]. If the FEurate exceeds 11%, it is consistent with either SIADH or RSW but 
repeating FEurate after correction of hyponatremia by any method, such as water restriction or 
administration of hypertonic saline, will differentiate SIADH from RSW; it will normalize to 4%–11% 
in SIADH and remain >11% in RSW. If the FEurate is normal, between 4% and 11%, it is most 
consistent with RO but can be seen in psychogenic polydipsia [43,44,46,47], and possibly in beer 
potomania. Psychogenic polydipsia can be readily diagnosed by the history of ingesting large volumes 
of water, having polyuria and excretion of dilute urines, and beer potomania by the history of ingesting 
large amounts of beer with low solute intake [42,43]. If the FEurate is <4%, it is consistent with  
pre-renal conditions including volume depleted states or inadequate perfusion with normal renal 
function as in true volume depletion, edematous states such as congestive heart failure, cirrhosis, 
nephrosis and pre-eclampsia [48]. The low FEurate in Addison’s disease can be explained by salt 
wasting due to a distal defect in sodium transport where mineralocorticoids exert their effect. The 
intact proximal tubule would thus increase the reabsorption of urate and other solutes as is typical of 
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pre-renal azotemia, FEurate <4% [48]. The dotted lines connecting a high FEurate with normonatremia 
and RSW can be supported by indirect data but it is our belief that this will eventually turn out to be a 
predictor of RSW without going through a phase of hyponatremia because the patient had very little 
water intake. This possibility is evident by the need to ingest water to become hyponatremic, since the 
insensible water losses are largely hypotonic to induce hypernatremia without sufficient water intake. 
Developing hyponatremia without water intake is extremely difficult if not impossible to achieve 
except if UNa exceeds serum sodium concentration in the absence of water intake. 
Figure 3. Algorithm for determining cause of hyponatremia, using FEurate. 
 
This algorithm omits a reliance on plasma renin, aldosterone, A/BNP, UNa or even the BUN to 
creatinine ratio. Plasma renin, aldosterone and A/BNP have not been consistently reliable indices 
because of the effect of saline infusions that are often utilized in hyponatremic patients, the presence of 
chronic kidney disease and frequent use of ACE inhibitors, angiotensin receptor blockers, diuretics and 
beta blockers. The determination of UNa has been utilized to evaluate patients with hyponatremia, but 
UNa <20 and even <40 mEq/L are being observed with greater frequency so this parameter has not 
proven to be effective in the evaluation of hyponatremic conditions. The low UNa in our experience 
has been observed much more commonly in patients with RSW as compared to patients with SIADH 
and RO. Since UNa reflects salt intake in conditions such as SIADH, RO and RSW, the low UNa 
suggests that these subjects have reduced intake of salt, probably reflecting the severity of their  
co-morbid condition. In some cases, the reduced salt intake could be iatrogenic. This has been reported 
with increased morbidity when the patient with RSW was fluid restricted for an erroneous diagnosis of 
SIADH [12,24,25,30]. This was the case in our RSW patient with a hip fracture whose UNa was  
6 mEq/L after being fluid restricted for 10 days for an erroneous diagnosis of SIADH [12,24,25]. The 
determination of UNa has not been useful in the evaluation of patients with hyponatremia. 
There is mounting evidence to prove the ineffectiveness of the volume approach to hyponatremia. 
Surprisingly, about a third of hyponatremic patients outside of the neurosurgical intensive care unit had 
RSW; the majority demonstrating no clinical evidence of cerebral disease; thus providing additional 
support for our proposal to change CSW to RSW [34,49]. As discussed, this is an important change,  
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prevalence of RSW was noted in a population where the “clinical” volume approach would have been 
attributed to SIADH because of the perception that SIADH is the most common cause of hyponatremia 
in this and all other clinical settings. This raises the possibility that the high morbidity and mortality rates 
associated with hyponatremia may have a significant iatrogenic component secondary to inappropriate 
water restriction in patients with RSW who were thought to have SIADH. These data provide further 
evidence for the ineffectiveness of the volume approach to evaluating patients with hyponatremia and 
support the common notion that we cannot assess the volume status of patients with any degree of 
accuracy. To persist in this outmoded approach will lead to misdiagnosis and mistreatment of patients 
with hyponatremia that will lead to increased morbidity and mortality of a group of patients with what 
appears to be more serious co-morbid conditions. The proposed algorithm has been found to be 
superior to the “clinical” volume approach and should be tested by other groups for its clinical 
effectiveness until newer algorithms can be developed.  
7. Conclusions 
It is extremely difficult to differentiate SIADH from RSW largely because of significant 
overlapping of clinical and laboratory findings and the perception that RSW is a rare clinical entity. 
This differentiation is extremely important because of divergent therapeutic goals of appropriately 
water restricting those with SIADH and increasing salt and water with RSW to avoid iatrogenic 
increases in morbidity and mortality. The recent recommendations to treat most or all patients with 
hyponatremia introduce an urgency to resolve this diagnostic and therapeutic dilemma. Changing CSW 
to RSW is an important modification in nomenclature that will expand our consideration of a large 
number of RSW patients without evidence of clinical cerebral disease and to avoid mismanagement 
and possibly reduce morbidity and mortality. The volume approach to hyponatremia and perception 
that RSW is a rare clinical entity should be abandoned in favor of a more open-minded approach that 
will lead to better diagnosis and treatment of hyponatremic conditions. To this end, we propose a new 
algorithm that utilizes FEurate as a pivotal determination, (Figure 3). Determining FEurate after 
correcting hyponatremia by judicious use of hypertonic saline might be an effective way of 
differentiating SIADH from RSW (Figure 1), being mindful of avoiding too rapid correction of 
hyponatremia to reduce the risk of developing osmotic demyelination, monitor the patient for any 
evidence of fluid overload such as induction of heart failure and that saline has a meager effect on 
FEurate. The new algorithm eliminates the determination of plasma renin, aldosterone and A/BNP and 
UNa, which have been found to be ineffective and often misleading. 
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